UBS Downgrades DLocal to Sell, Lowers Price Target to $14

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These human studies, crucial to drug development, can take years and accrue costs in the billions.